Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice

Cancer Investigation

Volumn 22, Issue 5, 2004, Pages 723-729

  Belo, Andrezza V ^a   Barcelos, Lucíola S ^a   Teixeira, Mauro M ^a   Ferreira, Mônica A N D ^a   Andrade, Silvia P ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Blood vessel formation; Clotrimazole; Inflammation; Thalidomide; Tumor

Indexed keywords

ACETYLGLUCOSAMINIDASE; CLOTRIMAZOLE; MYELOPEROXIDASE; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; HEMOGLOBIN DETERMINATION; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LEUKOCYTE; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL;

ACETYLGLUCOSAMINIDASE; ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CARCINOMA, EHRLICH TUMOR; CHEMOTAXIS, LEUKOCYTE; CLOTRIMAZOLE; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PEROXIDASE; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11244276982     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200032992     Document Type: Article

References (27)

1. D'Amore, P.A.; Thompson, R.W. Mechanisms of angiogenesis. Ann. Rev. Physiol. 1987, 49, 453-464.
2. Matter, A. Tumor angiogenesis as a therapeutic target. Drug Discov. Today 2001, 6 (19), 1005-1024.
3. Sheskin, J. Thalidomide in the treatment of lepra reaction. Clin. Pharmacol. Ther. 1965, 6, 303-306.
4. Benzaquen, L.R.; Brugnara, H.R.; Byers, S.; Gattom-Celli; Halperin, J.A. Clotrimazole inhibits cell proliferation in vitro and in vivo. Nat. Med. 1995, 1 (6), 534-540.
5. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 1994, 91, 4082-4085.
6. Kruse, F.E.; Joussen, K.; Rohrschneider, K.; Becker, M.B.; Volicker, H.E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe Arch. Clin. Exp. Ophtalmol. 1998, 236, 461-466.
7. 2+ stores, phosphorylation of eIF2α, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 8280-8285.
8. Dvorak, F.H. Tumors: wounds that do not heal. N. Eng. J. Med. 1986, 315, 1656-1659.
9. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to virchow? Lancet 2001, 357, 539-545.
10. Griffioen, A.; Molema, G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000, 52, 237-268.
11. Passaniti, A.; Taylor, R.M.; Pili, R.; et al. A simple, quantitative method for assessing angiogenesis and antiangiogenesis agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab. Invest. 1992, 67 (4), 519-528.
12. Lage, A.P.; Andrade, S.P. Assessment of angiogenesis and tumor growth in conscious mice by a fluorimetric method. Microvasc. Res. 2000, 59, 278-285.
13. Bailey, P.J. Sponge implants as models. Methods Enzymol. 1988, 162, 327-334.
14. Belo, A.V.; Ferreira, M.A.N.D.; Bosco, A.A.; Machado, R.D.P.; Andrade, S.P. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001, 25 (2), 91-96.
15. Fecchio, D.; Sirois, P.; Russo, M.; Jancar, S. Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity. Inflammation 1990, 14, 125-132.
16. Kohn, B.C.; Liotta, L.A. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995, 55, 1856-1862.
17. Bauer, K.S.; Cude, K.J.; Dixon, S.C.; Kruger, E.A.; Figg, W.D. Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric oxide synthase-vascular endothelial growth factor pathway. J. Pharmacol. Exp. Ther. 2000, 292, 31-37.
18. Kenyon, B.M.; Browne, F.; D'Amato, R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp. Eye Res. 1997, 64, 971-978.
19. Verheul, H.M.W.; Panigrahy, D.; Yuan, J.; D'Amato, R.J. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br. J. Cancer 1999, 79 (1), 114-118.
20. Gutman, M.; Szold, A.; Lazouskas, T.; Merimsky, O.; Klausner, J.M. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res. 1996, 16, 3673-3678.
21. Minchinton, A.I.; Fryer, K.H.; Wendt, K.R.; Clow, K.A.; Hayes, M.M.M. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996, 7, 339-343.
22. Scapini, P.; Nesi, L.; Morini, M.; et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J. Immunol. 2002, 168 (11), 5798-5804.
23. Ono, M.; Torisu, H.; Fukushi, J.; Nishie, A.; Kuwano, M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 1999, 43, S69-S71.
24. Crowther, M.; Brown, N.J.; Bishop, E.T.; Lewis, C.E. Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors. J. Leukoc. Biol. 2001, 70, 478-490.
25. Luo, J.C.; Yamaguchi, S.; Shitara, K.; Shibuya, M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res. 1998, 54, 2652-2658.
26. Morales, J.R.; Vélez, D.; Subiza, J.L. Ehrlich tumor stimulates extramedullar hematopoiesis in mice without secreting identifiable colony-stimulating factors and without engagement of host T cell. Exp. Hematol. 1999, 27, 1757-1767.
27. Tarabolette, G.; Margosio, B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. 2001, 1, 378-384.